GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celestra Inc (XKRX:352770) » Definitions » Notes Receivable

Celestra (XKRX:352770) Notes Receivable : ₩0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Celestra Notes Receivable?

Celestra's Notes Receivable for the quarter that ended in Dec. 2024 was ₩0 Mil.


Celestra Notes Receivable Historical Data

The historical data trend for Celestra's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celestra Notes Receivable Chart

Celestra Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Celestra Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Celestra Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Celestra Notes Receivable Related Terms

Thank you for viewing the detailed overview of Celestra's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Celestra Business Description

Traded in Other Exchanges
N/A
Address
Building 110, UNIST, 50, Suite 301-3, UNIST-gil, Eonyang-eup, Ulju-gun, Ulsan, KOR, 44919
Celestra Inc is a biotechnology company. The company provides early diagnosis of cancer/diseases based on genome and pursues to overcome aging and diseases through liquid biopsy and Multi-Omics technology. It offers a genome-based, early cancer diagnostic service through technology for multi-omics analysis and simultaneous detection of CTC and cfDNA in the blood based.

Celestra Headlines

No Headlines